Urinary Tract Infection Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

The Urinary Tract Infection Therapeutics Market is segmented By Drug (Penicillin and Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, and Nitrofurans), By Indication, and Geography.

Market Snapshot

Study Period:

2017-2025

Base Year:

2019

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

4.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Urinary Tract Infection Therapeutics Market is expected to register a CAGR of 4.1% during the forecast period. Certain factors that are driving the market growth include the increasing prevalence of diabetes and kidney stones and the launch of combination drugs.

  • According to a study published in Advances in Urology 2018, Kidney stone disease is an increasing urological disorder of human health which is affecting about 15% of the world population and it affects all age groups but occurs more frequently in men than in women within the age of 20–49 years. Moreover, during a lifetime, approximately 7% of women and 13% of men will develop a kidney stone.
  • Therefore, with the increasing prevalence of diabetes and kidney stones, the number of cases of urinary tract infection (UTI) increases, which in turn, increases the demand for drugs, thus, driving the global urinary tract infection therapeutics market.
  • Additionally, the launch of more efficient combination drugs and increasing geriatric population are expected to boost the growth of the urinary tract infection therapeutics market.
  • However, according to the Center for Education & Research on Therapeutics, over 2 million cases of adverse drug reactions (ADRs) are reported every year, leading to approximately 100,000 deaths.
  • According to the FDA, it is estimated that, in the United States, each year, over 350,000 ADRs occur in nursing homes alone.
  • With an increase in the number of cases of ADRs being reported, globally, there is an awareness among the population about the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
  • Additionally, the lack of awareness about the prevalence of UTIs in the developing and underdeveloped countries is also restraining the growth of the market.

Scope of the Report

As per the scope of the report, urinary tract infection (UTI) affects the urinary tract. It is one of the most common bacterial infections, and it is more common in women, as compared to men. UTI is considered as one of the frequent causes of morbidity and mortality, globally. The urinary tract infection therapeutics market is segmented by drug, indication, and geography.

Drug
Penicillin and Combinations
Quinolones
Cephalosporin
Azoles and Amphotericin B
Nitrofurans
Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)
Indication
Complicated UTI
Uncomplicated UTI
Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East & Africa
GCC
South Africa
Rest of Middle-East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Complicated UTIs Segment is Expected to Hold a Major Market Share in the Urinary Tract Infection Therapeutics Market

The prevalence of complicated UTI is expected to increase in the future, owing to the rise in drug-resistant bacteria and excessive use of antibiotics. A vast majority of physicians prescribe quinolones to treat complicated UTI cases. Cephalosporin is the second-most common drug prescribed for complicated UTI cases. 

According to the American Academy of Family Physicians (AAFP), kidney stones are a common disorder, with an annual incidence of eight cases per 1,000 adults. Moreover, around 13% of men and 7% of women develop a kidney stone in their lifetime and the overall incidence of urinary retention is 4.5 to 6.8 per 1,000 men, per year, in the United States. Overall, the prevalence of complicated UTI is set to increase during the forecast period, mainly owing to the increasing bacterial resistance in UTI cases and rise in recurrence rate for UTI.

To understand key trends, Download Sample Report

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The region is experiencing a drastic increase in innovations related to diagnostic methodologies used for UTIs. In recent events, during a routine checkup for UTI, a woman was observed to be infected by E. coli that showed resistance to the last-resort antibiotic, Colistin. The discovery of Colistin-resistant bacteria was considered a major issue. In addition to that, the CDC, in collaboration with other organizations, developed guidelines for the prevention of catheter-associated UTIs and other types of healthcare-associated infections in the United States. 

Furthermore, According to the Queensland Pediatric Factsheet 2019, estimates that approximately 1 in 10 girls and 1 in 50 boys will suffer from a urinary tract infection by seven years of age. Infections in children under one year are more common in boys but in older children infections are more common in girls. Thus, owing to the above factors the market is expected to show growth in the coming years.

To understand geography trends, Download Sample Report.

Competitive Landscape

The urinary tract infection therapeutics market is fragmented competitive and consists of a number of major players. Some of the companies which are currently dominating the market are AstraZeneca, Bayer AG, Cipla Inc., GlaxoSmithKline PLC, Shionogi & Co., Ltd, Novartis AG, and Pfizer, and others.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Diabetes and Kidney Stones

      2. 4.2.2 Launch of Combination Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Adverse Effects Associated with the Use of Medication

      2. 4.3.2 Lack of Awareness in the Developing and Underdeveloped Countries

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 Drug

      1. 5.1.1 Penicillin and Combinations

      2. 5.1.2 Quinolones

      3. 5.1.3 Cephalosporin

      4. 5.1.4 Azoles and Amphotericin B

      5. 5.1.5 Nitrofurans

      6. 5.1.6 Other Drugs (Aminoglycoside Antibodies, Sulphonamides, Tetracycline, etc.)

    2. 5.2 Indication

      1. 5.2.1 Complicated UTI

      2. 5.2.2 Uncomplicated UTI

      3. 5.2.3 Other Indications (Recurring Complicated UTI, Neurogenic Bladder Infection, etc.)

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca

      2. 6.1.2 Bayer AG

      3. 6.1.3 Cipla Inc.

      4. 6.1.4 GlaxoSmithKline PLC

      5. 6.1.5 Shionogi & Co., Ltd

      6. 6.1.6 Novartis AG

      7. 6.1.7 Pfizer

  7. *List Not Exhaustive
  8. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports